Results 121 to 130 of about 19,249 (228)

TREATMENT OF BLEEDING AND FACTOR VIII INHIBITORS IN ACQUIRED HEMOPHILIA A PATIENTS

Zdravniški Vestnik, 2004
Background. Bleeding in acquired hemophilia A patients with FVIII autoantibodies is often severe. The authors describe a successfuly acquired hemophilia A treatment with Feiba, glucocorticoids and cyclophosphamide in three patients.Results.
Peter Černelč, Janez Tomažič
doaj  

Diagnostics of congenital and acquired hemorrhagic diseases in patients with isolated prolonged activated partial thromboplastin time using laboratory algorithm [PDF]

, 2016
З метою розроблення алгоритму лабораторної діагностики розладів коагуляційного гемостазу і встановлення причини підвищеної схильності до кровотеч у 61 хворого з геморагічним синдромом було виконано скринінгові, 2 групи корекційних тестів (замінні проби ...
Красівська, В.В., Стасишин, О.В.   +1 more
core  

PB2323: ACQUIRED HEMOPHILIA: A CASE REPORT

HemaSphere, 2022
N. Haddad, S. ABDI
doaj   +1 more source

The management of hemophilia in elderly patients

Clinical Interventions in Aging, 2007
Massimo Franchini1, Annarita Tagliaferri2, Pier Mannuccio Mannucci31Transfusion and Hemophilia Center, City Hospital of Verona, Italy; 2Regional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, Italy; 3Angelo Bianchi ...
Massimo Franchini, Annarita Tagliaferri, Pier Mannuccio Mannucci   +2 more
doaj  

Acquired Hemophilia Developing After Whipple Operation

Acta Haematologica Oncologica Turcica
Acquired hemophilia A (AHA) is a rare bleeding disorder. It is caused by autoantibodies produced against endogenous coagulation factors, without a family history of hemophilia. The incidence has been reported as 1.4 per million.
Nebi Acar, İsmail Hasırcı
doaj   +1 more source

Hemophilia A - acquired during coronary artery bypass grafting [PDF]

Scripta Medica, 2013
We report a challenging case of a rare cause of post operative bleeding that occurred after the coronary artery by-pass graft procedure. We believe that acquired hemophilia A was the main culprit. Patient post CABG developed nonsurgical bleeding with new
Akintorin Abayomi, Alexander Bozana, Leila Ahmad Abou, Humanez Jose, Mcpencow James   +4 more
doaj  

Exploring RNA-targeted gene therapy approaches for hypertrophic cardiomyopathy [PDF]

, 2012
Relatório de projeto no âmbito do Programa de Bolsas Universidade de Lisboa/Fundação Amadeu Dias (2011/2012). Universidade de Lisboa.
Freitas, Ana
core  

cGMP Recombinant FIX for IV and Oral Hemophilia B Therapy [PDF]

, 2005
Three specific aims are proposed: Specific Aim # 1. Process engineer and scale-up the recovery and purification of transgenic recombinant human Factor IX.
Dernell, William, KEY PERSON, Julian, Cooper, LEAD INVESTIGATOR, Manning, Mark, LEAD INVESTIGATOR, Meagher, Michael, LEAD INVESTIGATOR, Mohanan, Paul, LEAD INVESTIGATOR, Nichols, Timothy, LEAD INVESTIGATOR, Stephan, Abramson, LEAD INVESTIGATOR, Swaanson, Todd, KEY PERSON, Van Cott, Kevin E., Velander, William H., PRINCIPAL INVESTIGATOR   +9 more
core   +1 more source

Technological Discontinuities and the Comparative Strategic Value of New Capabilites: Evidence from the Comparison of Small- and Large-Molecule Targeted Anti-Cancer Drug Discovery [PDF]

Traditional creative destruction theories distinguish disruptions as competence-destroying or competence-enhancing to incumbents’ capabilities, with the former case resulting in incumbents’ loss of competitive advantage in in-house R&D performance (even ...
M. Lourdes Sosa
core  

From laboratory to market: the biotechnology industry in the Third District [PDF]

In "From Laboratory to Market: The Biotechnology Industry in the Third District," Tim Schiller describes major biotechnology products and reviews estimates of the industry's size and scope. He also outlines where the industry is most active in the United
Timothy Schiller
core